DENTSPLY SIRONA Inc 8-K, filed Jan 13, 2026
DENTSPLY SIRONA Inc. (XRAY)
8-K
2026-01-13
For: 2026-01-10
View Original
Added on
April 11, 2026
About this 8-K
DENTSPLY SIRONA Inc filed this 8-K on January 13, 2026, reporting on events of January 10, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||||||||
(844 ) 848-0137
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 10, 2026, upon the recommendation of the Corporate Governance and Nominating Committee (the “Governance Committee”) of the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”), and in accordance with the Company’s By-laws, the Board approved an increase in the number of directors from 10 to 11, effective immediately.
Upon the further recommendation of the Governance Committee, the Board appointed Mr. Donald J. Zurbay to the Board, effective immediately. Mr. Zurbay will hold such office until the election of directors at the 2026 annual meeting of stockholders. Mr. Zurbay will serve as a member of the Audit and Finance Committee of the Board.
Mr. Zurbay does not have any family relationship with any director or executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Zurbay will participate in the same compensation plans as the other non-employee members of the Board, as described under “Directors’ Compensation” in the Company’s definitive proxy statement filed with the SEC on April 9, 2025 for the Company’s 2025 annual meeting of stockholders.
Item 7.01 Regulation FD Disclosure
The Company’s press release announcing the appointment of Mr. Zurbay as a member of the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
| DENTSPLY SIRONA Inc. Press Release Issued January 13, 2026 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DENTSPLY SIRONA Inc.
| By: | /s/ Daniel T. Scavilla | |||||||
| Name: | Daniel T. Scavilla | |||||||
| Title: | President and Chief Executive Officer | |||||||
Date: January 13, 2026
Dentsply Sirona Appoints Donald Zurbay to Board of Directors - Company’s Board of Directors forms Growth and Value Creation Committee to guide the Company’s Return-to-Growth Action Plan Charlotte, N.C., January 13, 2026 – DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the “Board”), effective January 10, 2026. He will be joining the Board’s Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership with Dentsply Sirona, giving Mr. Zurbay deep familiarity with the Company and its portfolio. Prior to Patterson, Mr. Zurbay served as CFO of St. Jude Medical, during which time the company delivered exceptional operational performance and long-term shareholder returns. Mr. Zurbay’s appointment was led by the Board’s Corporate Governance and Nominating Committee and aided by an independent search firm. Mr. Zurbay’s appointment further strengthens the Board’s capabilities in capital allocation and growth execution, supporting Dentsply Sirona’s ongoing focus on disciplined, sustainable value creation. With the addition of Mr. Zurbay, the Board has increased in size from 10 to 11 members. “Don’s deep understanding of the dental industry, combined with his experience driving transformation and growth in healthcare businesses, will be a valuable addition to our Board,” said Gregory T. Lucier, Chairman of the Board of Dentsply Sirona. “He brings a pragmatic, results-oriented leadership style and possesses complementary skills that will strengthen the Board’s culture and oversight capabilities as we execute our strategy to deliver long-term value creation.” “I’m excited to join the Board of Dentsply Sirona at such a pivotal time for the industry,” said Mr. Zurbay. “Through our previous partnership, I’ve seen firsthand the strength of the Company’s portfolio and its unique ability to transform dentistry. Dentsply Sirona’s leadership in innovation, scale, and clinical impact is unmatched, and I’m confident that the current management team and Board are exceptionally well-positioned to execute their growth strategy. I look forward to contributing my expertise in the dental market, industry dynamics, and innovation to help drive change and propel the Company forward in all markets.” Formation of Growth and Value Creation Committee The Board has established a special, ad hoc four-member Growth and Value Creation Committee, co- chaired by Mr. Lucier and Daniel T. Scavilla, the Company’s President & CEO. The Growth and Value Creation Committee will oversee and support the Board and management in executing the Company’s Return-to-Growth action plan outlined during the third-quarter 2025 earnings call on November 7, 2025. The Board remains highly engaged and fully supportive of the Company’s Return-to-Growth action plan, providing active oversight and guidance through structured engagement with management. Together with the Growth and Value Creation Committee, the Board will monitor the Company’s
progress, evaluate portfolio and growth opportunities, and ensure alignment with strategic priorities. This governance structure will enable timely decision-making, targeted support, and disciplined oversight, positioning management to execute the growth strategy with focus, urgency, and accountability. About Donald Zurbay Mr. Zurbay has more than 30 years of experience in finance and accounting, including 20 years spent in leadership positions within the global healthcare industry. Most recently, he was at Patterson Companies, Inc., a global healthcare company, serving as President and CEO, after previously serving as its CFO. Prior to Patterson, he worked in various leadership roles for St. Jude Medical, a global medical device company, culminating in his role as CFO. Mr. Zurbay serves on the Boards of Directors of Sight Sciences, Inc. and LivaNova PLC. He previously served on the Board of Directors and as Chair of the Audit Committee of Silk Road Medical, Inc. Mr. Zurbay holds a Bachelor of Science degree in Business from the University of Minnesota. He is a member of the American Institute of Certif ied Public Accountants and the Minnesota Society of Certified Public Accountants. About Dentsply Sirona Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products. Contact Information Investors: Wade Moody Senior Manager, Investor Relations InvestorRelations@dentsplysirona.com